Bicycle Therapeutics plc (BCYC)

Etorro trading 970x250
Bicycle Therapeutics plc (BCYC) Logo

About Bicycle Therapeutics plc

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company’s oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom. Address: Babraham Research Campus, Cambridge, United Kingdom, CB22 3AT

Bicycle Therapeutics plc News and around…

Latest news about Bicycle Therapeutics plc (BCYC) common stock and company :

Analysts Just Increased Price Targets of These 10 Stocks
18 Oct, 2021 Yahoo! Finance

In this article, we discuss the 10 stocks that analysts just increased price targets of. If you want to skip our detailed analysis of these stocks, go directly to Analysts Just Increased Price Targets of These 5 Stocks. The United States economy has rebounded strongly from the 2020 lows this year, posting incredible growth numbers […]

Bicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
18 Oct, 2021 FinancialContent

Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the closing on Friday, October 15, 2021 of its underwritten public offering of 3,726,852 American Depositary Shares (“ADSs”), each representing one ordinary share, which includes 486,111 ADSs sold upon the underwriters’ full exercise of their option to purchase additional ADSs. The offering resulted in gross proceeds of $201.3 million, before deducting underwriting discounts and commissions and offering expenses payable by Bicycle.

Bicycle Therapeutics Announces Pricing of Upsized Public Offering of $175 Million of American Depositary Shares
13 Oct, 2021 FinancialContent

Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the pricing of an underwritten public offering of 3,240,741 American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $54.00 per ADS, for gross proceeds of $175.0 million. In addition, Bicycle has granted the underwriters in the offering a 30-day option to purchase up to 486,111 additional ADSs at the public offering price. The offering is expected to close on or about October 15, 2021, subject to customary closing conditions.

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
12 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Bicycle Therapeutics Announces Proposed $125,000,000 Public Offering of American Depositary Shares
12 Oct, 2021 FinancialContent

Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that it has commenced an underwritten public offering of $125,000,000 of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs in the proposed offering will be sold by Bicycle. In connection with the offering, Bicycle intends to grant the underwriters in the offering a 30-day option to purchase up to an additional $18,750,000 of ADSs. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the offering.

BCYC Crosses Above Average Analyst Target
08 Oct, 2021 FinancialContent

In recent trading, shares of Bicycle Therapeutics plc (BCYC) have crossed above the average analyst 12-month target price of $47.33, changing hands for $48.69/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
08 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

45 Biggest Movers From Yesterday
08 Oct, 2021 FinancialContent

Gainers Camber Energy, Inc.. (NYSE: CEI) shares surged 95.9% to close at $1.78 on Thursday after dipping over 40% on Wednesday. ...

Bicycle Therapeutics Stock Falls After Interim Data Of Toxin Conjugates In Ovarian Cancer Trial
07 Oct, 2021 FinancialContent

Bicycle Therapeutics plc(NASDAQ: BCYC) hasreported interim Phase I trial results for BT5528 and preliminary ...

Bicycle Therapeutics Announces Interim BT5528 Phase I Clinical Trial Results and Preliminary Results from Ongoing BT8009 Phase I Clinical Trial
07 Oct, 2021 FinancialContent

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today provided a clinical update of its wholly-owned, next-generation Bicycle Toxin Conjugates (BTCs), reporting interim Phase I trial results for BT5528 and preliminary findings from the ongoing dose escalation portion of the BT8009 clinical trial.

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
07 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

12 Health Care Stocks Moving In Wednesday's Intraday Session
06 Oct, 2021 FinancialContent

Gainers Voyager Therapeutics (NASDAQ:VYGR) shares moved upwards by 44.73% to $3.58 during Wednesday's regular ...

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
06 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Bicycle Therapeutics PLC Sponsored ADR (BCYC) Surges 7%: Is This an Indication of Further Gains?
04 Oct, 2021 Yahoo! Finance

Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs, And More
03 Oct, 2021 FinancialContent

Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Here are the key catalysts that could move stocks in the unfolding week.

The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
03 Oct, 2021 FinancialContent

Biotech stocks came under pressure in the week endingOct. 1, dragged by broader market weakness and the selling ofvaccine ...

Bicycle Therapeutics to Present BT5528 Interim Phase I Data at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
30 Sep, 2021 FinancialContent

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that interim Phase I results from its Phase I/II trial of BT5528, a second-generation Bicycle® Toxin Conjugate (BTC™) targeting EphA2, has been selected for a plenary oral presentation at the upcoming AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, being held October 7-10, 2021. The Company will host a conference call to discuss the results and provide an update on preliminary findings from the BT8009 program on Thursday, October 7, 2021 at 3:00 p.m. ET.

Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
30 Sep, 2021 FinancialContent

Upgrades For Cabot Oil & Gas Corp (NYSE:COG), Wolfe Research upgraded the previous rating of Peer Perform to Outperform. For the ...

The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
17 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
16 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
10 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Bicycle Therapeutics Earnings Perspective: Return On Capital Employed
08 Sep, 2021 FinancialContent

Bicycle Therapeutics (NASDAQ:BCYC) brought in sales totaling $1.78 million during Q2 according to data provided by Benzinga Pro.However, ...

3 Biotech Stocks That Soared to New Heights Last Week
05 Sep, 2021 FinancialContent

Find out what these industry favorites are doing to impress investors.

The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
03 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
02 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
01 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Bicycle Therapeutics to Participate in Upcoming Investor Conferences
01 Sep, 2021 FinancialContent

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in the following investor conferences in September:

60 Biggest Movers From Yesterday
24 Aug, 2021 FinancialContent

Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be ...

Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Just Cut Their EPS Forecasts Substantially
07 Aug, 2021 Yahoo! Finance

One thing we could say about the analysts on Bicycle Therapeutics plc ( NASDAQ:BCYC ) - they aren't optimistic, having...

Bicycle Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
05 Aug, 2021 FinancialContent

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June 30, 2021 and provided recent corporate updates.

Bicycle Therapeutics plc (BCYC) is a NASDAQ Common Stock listed in , ,

970x250